Marco Matucci Cerinic
MD, PhD, FRCP, FBSRhon, FACR, FISR

Prof Marco Matucci Cerinic

You want to make an appointment with the Professor

Marco Matucci-Cerinic is Full Professor of Rheumatology at the Department of Experimental and Clinical Medicine of the University of Florence and works in the Rheumatology Division of the Careggi University Hospital of Florence. The professor is a member of the prestigious British Royal College of Physicians, the American College of Rheumatology, the Italian Society of Rheumatology and is also an honorary member of the British Society of Rheumatology.

Prof. Matucci-Cerinic has served as executive secretary of ILAR, vice president of SCTC, secretary general of EULAR and founder of the EUSTAR group. He is currently president of the World Scleroderma Foundation and editor of the Journal of Scleroderma & Related Diseases. He is also Associate Editor of the Arthritis Research & Therapy and Clinical Experimental Rheumatology journals and member of the board of the Annals of the Rheumatic Diseases, Rheumatology, Journal of Rheumatology, Scandinavian Journal of Rheumatology, Pulmonary Circulation and other rheumatology journals.

He has published more than 1000 scientific papers in the field of rheumatology, in particular on the pathogenesis, clinical features and treatment of Raynaud’s phenomenon, pulmonary, cardiac and vascular involvement (digital ulcers) of systemic sclerosis, rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and osteoarthritis.

Spoken languages

Patients & Care

His clinical activity is focused on the diagnosis and treatment of rheumatic diseases that afflict a large part of our population such as osteoarthritis, rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, Raynaud’s phenomenon and in particular a rare disease such as Systemic sclerosis (scleroderma). For the Tuscan Region, he ┬áhas directed the preparation of ┬áthe guidelines on rheumatic diseases and recently guided the creation of the Diagnostic Therapeutic Assistance Paths (PDTA) for Fibromyalgia and Systemic Sclerosis.

Diseases treated

The diseases treated are the following:
  • Inflammatory joint diseases: Rheumatoid Arthritis, Psoriatic Arthritis, Spondyloarthritis, Reactive Arthritis
  • Autoimmune connective tissue diseases: Raynaud’s phenomenon and Systemic Sclerosis, Sjogren’s syndrome, polymyositis and dermatomyositis, Antisynthetase syndromes, Mixed Connective Syndrome, Systemic Lupus Erythematosus
  • Vasculitis: Temporary or Horton Arteritis, granulomatosis associated with polyangiitis or Wegener’s granulomatosis, eosinophilic granulomatosis with polyangiitis or Churg-Strauss syndrome, polyarteritis nodosa or Kussmaul-Maier disease, Behcet syndrome
  • Degenerative joint diseases: Osteoarthritis, microcrystalline diseases such as Gout and Chondrocalcinosis
  • Bone diseases: Osteoporosis, Algodystrophy, Paget’s disease
  • Polimialgia e Fibromialgia

Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management